News

Kathleen Suozzi, MD, explains how UV damage shows up, why actinic keratoses matter, and which field therapies and lasers help cut skin cancer risk.

Low vitamin B12 levels link to longer-lasting wheals and heavier symptom burden in chronic spontaneous urticaria, suggesting a simple lab check for stubborn cases.

Clinicians at a Dermatology Times Case-Based Roundtable event worked through 3 vitiligo cases spanning new-onset, widespread, and pediatric disease, weighing treatment sequencing against real-world access barriers.

At a recent Dermatology Times Evolving Paradigms event led by Mark Nestor, MD, PhD, FAAD, dermatologists, Mohs surgeons, and oncologists compared immunotherapy mechanisms and referral thresholds for advanced CSCC.

Q32 Bio reported bempikibart reduced SALT scores by 35.3% and produced a SALT-20 response in 40.0% of patients at week 36 in the SIGNAL-AA phase 2a trial.

Black Girl Sunscreen founder Shontay Lundy debunks SPF myths for skin of color, urging education, representation, and teamwork for healthier skin.

Konika Patel Schallen, MD, discussed new findings showing the Nordlys 1940 nm non-ablative fractional laser may reverse epigenetic markers of skin aging in a recent Dermatology Times interview.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Roman Bronfenbrener, MD, discussed changing exit strategies, private equity, and why peer support may be one of the most valuable resources for independent dermatologists.

Do topical forms of PDRN actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Philip J. Mease, MD, reviews guselkumab's mechanism of action and its expanded FDA-approved indication for psoriatic arthritis joint damage inhibition.

Genetic MR links gut microbiome shifts to eczema, dermatitis, rosacea and more, spotlighting cytokines like IL‑10, IL‑18 and IL‑6 as therapeutic targets.

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed GX-03's encouraging interim safety profile, regulatory strategy, and next steps in clinical development.

Black Girl Sunscreen CEO and founder reveals why daily SPF matters for deeper skin tones, tackling white cast, education gaps, and inclusive sun care testing.

TRAPEDS-1 met its primary pharmacokinetic objective in children aged 6 to 11 years with moderate to severe atopic dermatitis, with no new safety signals over up to 172 weeks of tralokinumab treatment.

A new real-world study found CSU was linked to stress-related disorders, but not a broad increase in new-onset psychiatric disease.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!

Christopher Bunick, MD, PhD, shared practical guidance on sun protection, swimming, and preserving the skin barrier in patients with atopic dermatitis.

In this episode, Black Girl Sunscreen CEO Shontay Lundy reveals why skin of color needs photoprotection, better formulas, and stronger clinician-industry collaboration.

Forte Biosciences' FB102 shows significant facial repigmentation in a phase 1b vitiligo trial, with gains continuing 12 weeks post-treatment and mild adverse effects.

Learn the 10 weekly dashboard metrics Kathleen Moe, MD, tracks to spot issues early, boost access, cash flow, and patient experience in her practice.

Lynk Pharmaceuticals has dosed the first patient in a phase 2 trial evaluating investigational topical pan-JAK inhibitor LNK01004 for vitiligo.

Bradley Burnam, founder and CEO of Turn Therapeutics, explains the statistical rationale behind GX-03's phase 2 end point strategy and patient stratification.

Philip J. Mease, MD, explains the rationale for early biologic treatment in psoriatic arthritis following guselkumab's FDA label expansion to address structural joint damage.

A JAMA Dermatology study suggests higher cumulative isotretinoin doses, not higher daily doses, may help reduce acne relapse.

Roman Bronfenbrener, MD, discussed how dermatologists are using AI to streamline documentation, summarize patient records, support clinical decision-making, and improve practice operations.

FDA clears SkinStylus microneedling for under-eye wrinkles in all skin types, expanding uses for acne and abdominal scars amid booming aesthetics demand.

The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.

This review of the latest dermatological studies includes insights on granulomatous dermatoses during dupilumab therapy, SAAD-41 validation in alopecia, updated vitiligo trends, and more.